Combined Package of Interventions for Environmental Enteropathy
Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Machinga Distric
-
Limela, Machinga Distric, Malawi
- Limela Rural Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- children residing in catchment area of Limela, Machinga District, Malawi
- aged 12-35 months
- youngest eligible child in each household
Exclusion Criteria:
- severe acute malnutrition
- severe chronic illness
- children unable to drink 20 mL of dual sugar solution
- children in need of acute medical treatment for illness or injury at time of enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Multiple Intervention Arm
single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
|
|
|
PLACEBO_COMPARATOR: Placebo
three placebos
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dual Sugar Absorption Test
Time Frame: 12 weeks
|
lactulose-mannitol ratio in urine
|
12 weeks
|
|
Dual Sugar Absorption Test
Time Frame: 24 weeks
|
lactulose-mannitol ratio in urine
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lactulose Excretion
Time Frame: 12 weeks
|
percentage of ingested lactulose excreted in urine
|
12 weeks
|
|
Lactulose Excretion
Time Frame: 24 weeks
|
percentage of ingested lactulose excreted in urine
|
24 weeks
|
|
Mannitol Excretion
Time Frame: 12 weeks
|
percentage of ingested mannitol excreted in urine
|
12 weeks
|
|
Mannitol Excretion
Time Frame: 24 weeks
|
percentage of ingested mannitol excreted in urine
|
24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Chrissie Thakwalakwa, PhD, University of Malawi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Micronutrients
- Trace Elements
- Albendazole
Other Study ID Numbers
Other Study ID Numbers
- EE-zinc-alb-micronut
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Environmental Enteropathy
-
NCT01593033Completed
-
NCT05608928Not yet recruiting
-
NCT02472301Completed
-
NCT05501470RecruitingEnvironmental Enteric Dysfunction
-
NCT01832636CompletedDiarrhea | Malnutrition | Environmental Enteropathy
-
NCT03713502Active, not recruitingDiabetes | HIV | Environmental Enteropathy
-
NCT04565821Active, not recruitingInflammatory Bowel Diseases | Crohn Disease | Permeability; Increased | Inflammatory Disease | Environmental Enteropathy
-
NCT06003881Approved for marketingCD55-Deficient Protein-Losing Enteropathy
-
NCT04209634CompletedCD55-deficient Protein-losing Enteropathy | CHAPLE
-
NCT05474664CompletedFontan Operation | Protein-Losing Enteropathy | Camostat Mesylate
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04388215UnknownHypertension | Dyslipidemias
-
NCT04693039Completed
-
NCT01610388Completed